Boston Tech
Superluminal Medicines Raised $60 Million to Make an Appetite Switch Pick a Lane
Boston biotech Superluminal Medicines raised $60 million to take an AI-designed oral drug for rare genetic obesity into its first human trial.
Boston Tech
Boston biotech Superluminal Medicines raised $60 million to take an AI-designed oral drug for rare genetic obesity into its first human trial.
Boston Tech
Cambridge startup Physical Superintelligence raised $58 million to build AI virtual physicists, starting with data-center power and cooling.
Boston Tech
Cambridge startup Transfyr raised $25 million to turn lab work into machine-readable data for reproducibility, training, and scientific automation.
Boston Tech
Somerville startup Diffraqtion raised over $10 million to build quantum cameras for sharper, faster space and defense sensing with smaller optics.
Boston Tech
MIT-born Julia now serves over one million users and powers JuliaHub’s physics-aware Dyad tools, a serious Boston bet on engineering software.
Boston Tech
Liquid AI’s Pipette benchmarks on-device AI across models, quantization, runtimes, and real hardware, making edge performance easier to inspect.
Boston Tech
Massachusetts opened $500,000-to-$2 million grants for climate-tech and life-sciences facilities, betting the next breakthrough needs actual machinery.
Boston Tech
Cambridge startup Apollo Atomics raised $31 million to build compact, factory-made nuclear reactors around a radically smaller steam generator.
Boston Tech
Moderna and Merck say their personalized mRNA cancer vaccine met Phase 3 melanoma endpoints. The Cambridge biotech has a real win, with caveats.
Boston Tech
Cambridge venture firm Floating Point is targeting a $120 million third fund for complex startups in healthcare, energy, logistics, and defense.
Boston Tech
Cambridge AI music company Suno partnered with BMG on a new industry-developed model, turning copyright pressure into a serious licensing bet.
Boston Tech
Burlington’s Azenta grew 12% in Q3 as biotech demand lifted sample management and multiomics, but quality costs keep the turnaround honest.